

■ MDA-MD-231 cells

Human MDA-MD-231 cells were isolated from the pleural effusion of a patient with metastatic triple negative breast adenocarcinoma.

■ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing MDA-MD-231 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the MDA-MD-231 cells as xenograft
Mean \pm SEM (n=5; take rate 100%)

Antineo can also implant this model orthotopically.

■ Standard-Of-Care Drug Responses

Taxol 10 mg/kg, qw, IP \rightarrow Response




Figure 2: Effect of taxol treatment on MDA-MD-231 tumour growth
Mean \pm SEM (n=4 per group; take rate 100%)

A MDA-MD-231 GFP +, with a high metastasis propensions developed *in vivo* is available at Antineo (model ID MDA-MD-231 GFP).